Phase 1a/b open-label study of IK-175, an oral AHR inhibitor, alone and in combination with nivolumab in patients with locally advanced or metastatic solid tumors and urothelial carcinoma

被引：0
作者：
McKean, Meredith
Aggen, David Henry
Lakhani, Nehal J.
Bashir, Babar
Luke, Jason J.
Hoffman-Censits, Jean H.
Alhalabi, Omar
Bowman, Isaac Alex
Guancial, Elizabeth A.
Tan, Alan
Lingaraj, Trupti
Timothy, Marissa
Kacena, Katherine
Malek, Karim S.
Santillana, Sergio
机构：
[1] Sarah Cannon Res Inst, Tennessee Oncol, PLLC, Nashville, TN USA
[2] Mem Sloan Kettering Canc Ctr, New York, NY USA
[3] START Midwest, Grand Rapids, MI USA
[4] Thomas Jefferson Univ, Sarah Cannon Res Inst, Philadelphia, PA USA
[5] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA USA
[6] Univ Pittsburgh, Pittsburgh, PA USA
[7] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[8] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[9] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[10] Florida Canc Specialists, Sarasota, FL USA
[11] Rush Univ, Med Ctr, Chicago, IL USA
[12] Ikena Oncol, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3169
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A PHASE 1A/B STUDY OF IK-175, AN ORAL AHR INHIBITOR, ALONE AND IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH LOCALLY DVANCED OR METASTATIC SOLID TUMORS AND UROTHELIAL CARCINOMA
    McKean, Meredith
    Luke, Jason
    Lakhani, Nehal
    Bashir, Babar
    Aggen, David
    Tan, Alan
    Kacena, Katherine
    Wang, Lei
    Timothy, Marissa
    Santillana, Sergio
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A425 - A425
  • [2] INITIAL RESULTS FROM A PHASE 1A/B STUDY OF IK175, AN ORAL AHR INHIBITOR, AS A SINGLE AGENT AND IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS AND UROTHELIAL CARCINOMA
    Aggen, David
    McKean, Meredith
    Lakhani, Nehal
    Bashir, Babar
    Hoffman-Censits, Jean
    Alhalabi, Omar
    Guancial, Elizabeth
    Bowman, Isaac
    Tan, Alan
    Lingaraj, Trupti
    Timothy, Marissa
    Ortiz-Otero, Nerymar
    Bartolini, Wilmin
    Kacena, Katherine
    Malek, Karim
    Santillana, Sergio
    Luke, Jason
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A692 - A692
  • [3] A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors
    Mettu, Niharika B.
    Ulahannan, Susanna, V
    Bendell, Johanna C.
    Garrido-Laguna, Ignacio
    Strickler, John H.
    Moore, Kathleen N.
    Stagg, Robert
    Kapoun, Ann M.
    Faoro, Leonardo
    Sharma, Sunil
    CLINICAL CANCER RESEARCH, 2022, 28 (05) : 882 - 892
  • [4] A PHASE 1B OPEN-LABEL, SINGLE-ARM DOSE EXPANSION STUDY OF IK-175, AN ORAL AHR INHIBITOR, IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH PRIMARY PD-1 INHIBITOR RESISTANT ADVANCED HEAD AND NECK CANCER
    Lingaraj, Trupti
    Timothy, Marissa
    Ortiz-Otero, Nerymar
    Bartolini, Wilmin
    Kacena, Katherine
    Malek, Karim
    Santillana, Sergio
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A710 - A710
  • [5] IK-175, an oral AHR inhibitor, as monotherapy and in combination with nivolumab in patients with urothelial carcinoma resistant/refractory to PD-1/L1 inhibitors
    Aggen, David H.
    McKean, Meredith
    Hoffman-Censits, Jean H.
    Lakhani, Nehal J.
    Alhalabi, Omar
    Guancial, Elizabeth A.
    Bashir, Babar
    Bowman, I. Alex
    Tan, Alan
    Lingaraj, Trupti
    Kim, Katherine
    Timothy, Marissa
    Ortiz-Otero, Nerymar
    Bartolini, Wilmin
    Kacena, Katherine
    Santillana, Sergio
    Luke, Jason J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] ATLAS: A Phase II, open-label study of rucaparib in patients with locally advanced or metastatic urothelial carcinoma
    Grivas, Petros
    Teo, Min Yuen
    Vogelzang, Nicholas
    Alva, Ajjai
    Zakharia, Yousef
    Adra, Nabil
    Drakaki, Alexandra
    Hussain, Arif
    Morales-Barrera, Rafael
    Necchi, Andrea
    Rodriguez-Vida, Alejo
    Feyerabend, Susan
    Gupta, Sumati
    Josephs, Debra H.
    Loriot, Yohann
    Srinivas, Sandy
    Wride, Kenton
    Thomas, Daleen
    Dusek, Rachel
    Simmons, Andrew D.
    Nepert, Dale
    Chowdhury, Simon
    CANCER RESEARCH, 2019, 79 (13)
  • [7] ATLAS: a phase 2, open-label study of rucaparib in patients with locally advanced (unresectable) or metastatic urothelial carcinoma
    Feyerabend, S.
    Boegemann, M.
    Goebell, P. J.
    Stoeckle, M.
    Nepert, D.
    Wride, K.
    Thomas, D.
    Loehr, A.
    Simmons, A.
    Grivas, P.
    Chowdhury, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 324 - 324
  • [8] ATLAS: A phase II open-label study of rucaparib in patients with locally advanced or metastatic urothelial carcinoma (mUC).
    Grivas, Petros
    Vogelzang, Nicholas J.
    Alva, Ajjai Shivaram
    Feyerabend, Susan
    Loriot, Yohann
    Necchi, Andrea
    Gupta, Sumati
    Josephs, Debra Hannah
    Rodriguez-Vida, Alejo
    Srinivas, Sandy
    Zakharia, Yousef
    Wride, Kenton
    Thomas, Daleen
    Dusek, Rachel
    Simmons, Andrew
    Nepert, Dale L.
    Chowdhury, Simon
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [9] ATLAS: A phase II, open-label study of rucaparib in patients (pts) with locally advanced (unresectable) or metastatic urothelial carcinoma
    Chowdhury, S.
    Feyerabend, S.
    Loriot, Y.
    Necchi, A.
    Gupta, S.
    Josephs, D. H.
    Rodriguez-Vida, A.
    Srinivas, S.
    Zakharia, Y.
    Nepert, D.
    Wride, K.
    Thomas, D.
    Loehr, A.
    Simmons, A. D.
    Grivas, P.
    ANNALS OF ONCOLOGY, 2018, 29
  • [10] ATLAS: A phase 2, open-label study of rucaparib in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC).
    Grivas, Petros
    Nepert, Dale L.
    Wride, Kenton
    Thomas, Daleen
    Loehr, Andrea
    Simmons, Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345